A citation-based method for searching scientific literature

Mizuki Nishino, Hiroto Hatabu, F Stephen Hodi. Radiology 2019
Times Cited: 96







List of co-cited articles
764 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Lesley Seymour, Jan Bogaerts, Andrea Perrone, Robert Ford, Lawrence H Schwartz, Sumithra Mandrekar, Nancy U Lin, Saskia Litière, Janet Dancey, Alice Chen,[...]. Lancet Oncol 2017
36

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
33

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Jedd D Wolchok, Axel Hoos, Steven O'Day, Jeffrey S Weber, Omid Hamid, Celeste Lebbé, Michele Maio, Michael Binder, Oliver Bohnsack, Geoffrey Nichol,[...]. Clin Cancer Res 2009
26

Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
Sree Harsha Tirumani, Nikhil H Ramaiya, Abhishek Keraliya, Nancy D Bailey, Patrick A Ott, F Stephen Hodi, Mizuki Nishino. Cancer Immunol Res 2015
173
23

PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.
Mizuki Nishino, Nikhil H Ramaiya, Mark M Awad, Lynette M Sholl, Jennifer A Maattala, Myriam Taibi, Hiroto Hatabu, Patrick A Ott, Philippe F Armand, F Stephen Hodi. Clin Cancer Res 2016
288
20

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Roger Sun, Elaine Johanna Limkin, Maria Vakalopoulou, Laurent Dercle, Stéphane Champiat, Shan Rong Han, Loïc Verlingue, David Brandao, Andrea Lancia, Samy Ammari,[...]. Lancet Oncol 2018
522
19

Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel,[...]. N Engl J Med 2010
17

Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements.
Mizuki Nishino, Anita Giobbie-Hurder, Maria Gargano, Margaret Suda, Nikhil H Ramaiya, F Stephen Hodi. Clin Cancer Res 2013
321
17

Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome.
Mizuki Nishino, Suzanne E Dahlberg, Anika E Adeni, Christine A Lydon, Hiroto Hatabu, Pasi A Jänne, F Stephen Hodi, Mark M Awad. Clin Cancer Res 2017
53
30

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
F Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jeffrey S Weber, Adil Daud, Omid Hamid, Amita Patnaik, Antoni Ribas, Caroline Robert, Tara C Gangadhar,[...]. J Clin Oncol 2016
496
15

Monitoring immune-checkpoint blockade: response evaluation and biomarker development.
Mizuki Nishino, Nikhil H Ramaiya, Hiroto Hatabu, F Stephen Hodi. Nat Rev Clin Oncol 2017
552
15

Pseudoprogression and Immune-Related Response in Solid Tumors.
Victoria L Chiou, Mauricio Burotto. J Clin Oncol 2015
553
15

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
Jarushka Naidoo, Xuan Wang, Kaitlin M Woo, Tunc Iyriboz, Darragh Halpenny, Jane Cunningham, Jamie E Chaft, Neil H Segal, Margaret K Callahan, Alexander M Lesokhin,[...]. J Clin Oncol 2017
608
15


Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings.
Gary X Wang, Vikram Kurra, Justin F Gainor, Ryan J Sullivan, Keith T Flaherty, Susanna I Lee, Florian J Fintelmann. Radiographics 2017
67
20

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
14

Novel patterns of response under immunotherapy.
E Borcoman, Y Kanjanapan, S Champiat, S Kato, V Servois, R Kurzrock, S Goel, P Bedard, C Le Tourneau. Ann Oncol 2019
229
14

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.
Frederike Bensch, Elly L van der Veen, Marjolijn N Lub-de Hooge, Annelies Jorritsma-Smit, Ronald Boellaard, Iris C Kok, Sjoukje F Oosting, Carolina P Schröder, T Jeroen N Hiltermann, Anthonie J van der Wekken,[...]. Nat Med 2018
322
13

Ipilimumab associated hepatitis: imaging and clinicopathologic findings.
Kyung Won Kim, Nikhil H Ramaiya, Katherine M Krajewski, Jyothi P Jagannathan, Sree Harsha Tirumani, Amitabh Srivastava, Nageatte Ibrahim. Invest New Drugs 2013
168
13

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
13

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Daniel Y Wang, Joe-Elie Salem, Justine V Cohen, Sunandana Chandra, Christian Menzer, Fei Ye, Shilin Zhao, Satya Das, Kathryn E Beckermann, Lisa Ha,[...]. JAMA Oncol 2018
13


Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.
Mizuki Nishino, Anita Giobbie-Hurder, Hiroto Hatabu, Nikhil H Ramaiya, F Stephen Hodi. JAMA Oncol 2016
421
13

Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.
Mizuki Nishino, Hiroto Hatabu, Lynette M Sholl, Nikhil H Ramaiya. Radiographics 2017
43
30

Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events.
Jennifer J Kwak, Sree Harsha Tirumani, Annick D Van den Abbeele, Phillip J Koo, Heather A Jacene. Radiographics 2015
118
13

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, Michael B Atkins, Kelly J Brassil, Jeffrey M Caterino, Ian Chau, Marc S Ernstoff, Jennifer M Gardner, Pamela Ginex,[...]. J Clin Oncol 2018
13

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
Stéphane Champiat, Laurent Dercle, Samy Ammari, Christophe Massard, Antoine Hollebecque, Sophie Postel-Vinay, Nathalie Chaput, Alexander Eggermont, Aurélien Marabelle, Jean-Charles Soria,[...]. Clin Cancer Res 2017
759
12

Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.
Mizuki Nishino, Anita Giobbie-Hurder, Michael P Manos, Nancy Bailey, Elizabeth I Buchbinder, Patrick A Ott, Nikhil H Ramaiya, F Stephen Hodi. Clin Cancer Res 2017
80
15

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.
M Tazdait, L Mezquita, J Lahmar, R Ferrara, F Bidault, S Ammari, C Balleyguier, D Planchard, A Gazzah, J C Soria,[...]. Eur J Cancer 2018
198
12

Ipilimumab-associated colitis: CT findings.
Kyung Won Kim, Nikhil H Ramaiya, Katherine M Krajewski, Atul B Shinagare, Stephanie A Howard, Jyothi P Jagannathan, Nageatte Ibrahim. AJR Am J Roentgenol 2013
106
12

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Roberto Ferrara, Laura Mezquita, Matthieu Texier, Jihene Lahmar, Clarisse Audigier-Valette, Laurent Tessonnier, Julien Mazieres, Gerard Zalcman, Solenn Brosseau, Sylvestre Le Moulec,[...]. JAMA Oncol 2018
439
12

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Scott N Gettinger, Leora Horn, Leena Gandhi, David R Spigel, Scott J Antonia, Naiyer A Rizvi, John D Powderly, Rebecca S Heist, Richard D Carvajal, David M Jackman,[...]. J Clin Oncol 2015
864
12

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
Michael A Postow, Robert Sidlow, Matthew D Hellmann. N Engl J Med 2018
12

Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers.
S Trebeschi, S G Drago, N J Birkbak, I Kurilova, A M Cǎlin, A Delli Pizzi, F Lalezari, D M J Lambregts, M W Rohaan, C Parmar,[...]. Ann Oncol 2019
222
12

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma.
Steve Y Cho, Evan J Lipson, Hyung-Jun Im, Steven P Rowe, Esther Mena Gonzalez, Amanda Blackford, Alin Chirindel, Drew M Pardoll, Suzanne L Topalian, Richard L Wahl. J Nucl Med 2017
139
11

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
11

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
10

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.
Richard L Wahl, Heather Jacene, Yvette Kasamon, Martin A Lodge. J Nucl Med 2009
10

Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor.
Francesco Alessandrino, Sonia Sahu, Mizuki Nishino, Anika E Adeni, Sree Harsha Tirumani, Atul B Shinagare, Mark M Awad. Abdom Radiol (NY) 2019
26
38

Immunotherapy and the role of imaging.
Brett W Carter, Priya R Bhosale, Wei T Yang. Cancer 2018
54
18

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.
Mizuki Nishino, Lynette M Sholl, F Stephen Hodi, Hiroto Hatabu, Nikhil H Ramaiya. N Engl J Med 2015
268
10

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Monica Khunger, Sagar Rakshit, Vinay Pasupuleti, Adrian V Hernandez, Peter Mazzone, James Stevenson, Nathan A Pennell, Vamsidhar Velcheti. Chest 2017
269
10

Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management.
Kevin R Kalisz, Nikhil H Ramaiya, Kai R Laukamp, Amit Gupta. Radiographics 2019
66
15

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
9

Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1.
Ahmed Mekki, Laurent Dercle, Philip Lichtenstein, Aurélien Marabelle, Jean-Marie Michot, Olivier Lambotte, Jérôme Le Pavec, Eleonora De Martin, Corinne Balleyguier, Stéphane Champiat,[...]. Eur J Cancer 2018
80
11

Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report.
Ilke Tunali, Jhanelle E Gray, Jin Qi, Mahmoud Abdalah, Daniel K Jeong, Albert Guvenis, Robert J Gillies, Matthew B Schabath. Lung Cancer 2019
78
11

Pembrolizumab for the treatment of non-small-cell lung cancer.
Edward B Garon, Naiyer A Rizvi, Rina Hui, Natasha Leighl, Ani S Balmanoukian, Joseph Paul Eder, Amita Patnaik, Charu Aggarwal, Matthew Gubens, Leora Horn,[...]. N Engl J Med 2015
9

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.
F Stephen Hodi, Marcus Ballinger, Benjamin Lyons, Jean-Charles Soria, Mizuki Nishino, Josep Tabernero, Thomas Powles, David Smith, Axel Hoos, Chris McKenna,[...]. J Clin Oncol 2018
193
9

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J B A G Haanen, F Carbonnel, C Robert, K M Kerr, S Peters, J Larkin, K Jordan. Ann Oncol 2017
9

Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis.
Hyo Jung Park, Kyung Won Kim, Junhee Pyo, Chong Hyun Suh, Shinkyo Yoon, Hiroto Hatabu, Mizuki Nishino. Radiology 2020
39
23


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.